Articles Tagged With: chagas
-
New Agent for Treatment of Chagas Disease Disappoints in Clinical Trial
A randomized, controlled trial of E1224 (a ravuconazole prodrug) in different doses and durations was studied in adult patients with chronic indeterminate Chagas disease. Parasite clearance was observed in treated patients, but the response was transient in most patients.
-
Anti-parasitic Therapy of Chronic Chagas’ Cardiomyopathy
Two thousand eight hundred fifty-four patients with Chagas’ cardiomyopathy were randomized to benznidazole or placebo, were treated for up to 80 days, and were followed for a mean of 5.4 years. Trypanocidal treatment with benznidazole reduced serum parasite detection but did not reduce clinical cardiac deterioration.
-
Chagas — Multifaceted Approach Needed
Prolonged recurrent exposure to Trypanosoma cruzi leads to an increased risk of inflammatory cardiomyopathy, but to decreased congenital transmission of T. cruzi. As housing and vector control improve, concurrent attention to early treatment is needed in order to reduce both cardiomyopathy and congenital infection.